Out-licensing early-stage pipelines is the worst option. China Biotech at a critical point in verifying business models. CNPGC has other methods to address the horizontal competition issue with Taiji.
What is covered in the Full Insight:
Introduction to Drug Commercialization
Biotech Model Validation in China
Challenges with CNPGC and Taiji Group
Market Review
Risk Disclosure
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.